The first component of the collaboration with Wave will focus on programs targeting Huntington's disease, amyotrophic lateral sclerosis (commonly referred to as Lou Gehrig's disease), frontotemporal dementia, and spinocerebellar ataxia type 3, with the option to co-develop and co-commercialize after demonstration of clinical proof of mechanism..
Wave is developing oligonucleotide therapeutics to target diseases that have been historically difficult to treat with small molecules or biologics. Their molecules are designed to reduce the expression of disease-promoting proteins or to transform the production of dysfunctional mutant proteins into the production of functional proteins, with the potential of treating the targeted disease.
The second component of the collaboration provides Takeda with the rights to exclusively license multiple preclinical programs targeting other neurological disorders including Alzheimer's disease and Parkinson's disease. At any one time during a four-year term, the companies may collaborate on up to six preclinical programs.
Takeda is a research-based global company with its main focus on pharmaceuticals. The company has a commercial presence covering around 70 countries, with particular strength in Asia, North America, Europe, and fast-growing emerging markets including Latin America, Russia-CIS and China. Areas of R and D focus include central nervous system, cardiovascular and metabolic, gastroenterology, oncology, and vaccines.
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials